Getting to Patient Centricity
This whitepaper explores the advancement of patient centricity across the industry and offers tips on how pharma and biotech firms can successfully navigate the patient centricity journey.
Patient centricity has emerged in recent years as a top priority for most Pharma and Biotech firms
However, for many, this journey has been slow and with many bumps along the way. While it’s always difficult to bring about cultural, strategic, and operational transformation in large organizations, the structural complexity of the health care environments in which many Pharma and Biotech firms are operating makes profound organizational change even more difficult.
As managers work to make their organizations more patient-centric, even basic questions such as “what do we mean when we state that we are patient-centric?”, “what processes do we need to have in place?”, “are we making progress?” or, simply, “how do we get started in transforming our company?” frequently arise.
This whitepaper explores the advancement of patient centricity across the industry and offers tips on how pharma and biotech firms can successfully navigate the patient centricity journey.
Organic Growth Playbook Keynote
In February 2020, CapSys held a client event in Zurich, hosting a keynote presentation from Robert S. Lurie, the co-author of the Organic Growth Playbook (OGP). The book is part of an American Marketing Association’s book series and was awarded the Leonard L. Berry Marketing Book Award for 2019.
OGP draws on decades of consulting, corporate and academia work by the authors and is the natural evolution of the methodology commonly used for strategic / brand planning. The keynote and Q&A session focused on the applicability of the approach and the motivations to update it.
Profitable Growth in Recessionary Times
The Covid-19 pandemic is an unprecedented public health and economic shock. We can confidently say that the “new normal”, when it emerges, includes a deep recession and an acute capacity crisis in healthcare systems worldwide. How long they will last and how deep will be the effects, we don’t yet know.
Recent history, especially the 2008 financial crisis, has shown that – even in highly uncertain times – companies can react with a longer-term view to defend, share or even achieve continued growth. Our presentation at the 2020 Eyeforpharma virtual conference looks at pertinent case studies to understand what Life Sciences companies have done and identify choices and strategies that proved successful.
